Donate

New Data Supports Safety & Efficacy Claims of ALPROLIX

August 17, 2015

Note: This is an edited form of a press release from Biogen. To read the original release in its entirety, click here.  New clinical data support the long-term safety and efficacy of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two years, Biogen announced on […]

Five New Developments in Hemophilia

April 7, 2015

This post first appeared on Vector, a blog of Boston Children’s Hospital an was written by Ellis Neufeld, MD, PhD, a hematologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.   ________________________________________________ From new longer-acting drugs to promising gene therapy trials, much is changing in the treatment of hemophilia, the inherited bleeding disorder in which the blood does not clot. […]

FDA Accepts CSL Behring’s Application for New Long-Acting Hemophilia B Product

February 4, 2015

This is an edited version of a press release from CSL Behring. To read the full release, please click here. ____________________  CSL Behring announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.